메뉴 건너뛰기




Volumn 17, Issue 6, 1997, Pages 1296-1299

Experience with crystalline niacin as the preferred drug for dyslipidemia in a specialty clinic

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINIC ACID;

EID: 0030662291     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (5)

References (21)
  • 1
    • 0025183769 scopus 로고
    • Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B
    • Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
    • (1990) N Engl J Med , vol.323 , pp. 1289-1298
    • Brown, G.1    Albers, J.J.2    Fisher, L.D.3
  • 2
    • 0023001772 scopus 로고
    • Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin
    • Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
    • (1986) J Am Coll Cardiol , vol.8 , pp. 1245-1255
    • Canner, P.L.1    Berge, K.G.2    Wenger, N.K.3
  • 3
    • 1842338863 scopus 로고
    • Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration
    • Dunn RT, Ford MA, Rindone JP, Kwiecinski FA. Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther 1995;2:478-80.
    • (1995) Am J Ther , vol.2 , pp. 478-480
    • Dunn, R.T.1    Ford, M.A.2    Rindone, J.P.3    Kwiecinski, F.A.4
  • 4
    • 0027243348 scopus 로고
    • Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II)
    • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993;269:3015-23.
    • (1993) JAMA , vol.269 , pp. 3015-3023
  • 5
    • 0015348189 scopus 로고
    • Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative centrifuge
    • Friedewald WT, Levy RI, Tredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative centrifuge. Clin Chem 1972;18:499-502.
    • (1972) Clin Chem , vol.18 , pp. 499-502
    • Friedewald, W.T.1    Levy, R.I.2    Tredrickson, D.S.3
  • 6
    • 0029924834 scopus 로고    scopus 로고
    • Effectiveness of low-dose crystalline nicotinic acid in men with low highdensity lipoprotein cholesterol levels
    • Martin-Jadraque R, Tato F, Mostaza JM, et al. Effectiveness of low-dose crystalline nicotinic acid in men with low highdensity lipoprotein cholesterol levels. Arch Intern Med 1996:156:1081-8.
    • (1996) Arch Intern Med , vol.156 , pp. 1081-1088
    • Martin-Jadraque, R.1    Tato, F.2    Mostaza, J.M.3
  • 7
    • 0027963479 scopus 로고
    • Comparative effects of lovastatin and niacin in primary hypercholesterolemia
    • Illingworth DR, Stein EA, Mitchell YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. Arch Intern Med 1994;154:1586-95.
    • (1994) Arch Intern Med , vol.154 , pp. 1586-1595
    • Illingworth, D.R.1    Stein, E.A.2    Mitchell, Y.B.3
  • 8
    • 0016630250 scopus 로고
    • Clofibrate and niacin in coronary heart disease
    • The Coronary Drug Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
    • (1975) JAMA , vol.231 , pp. 360-381
  • 9
    • 0028057319 scopus 로고
    • Comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients
    • McKenny JM, Proctor JD, Harris S, Chinchili VM. Comparison of the efficacy and toxic effects of sustained-vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-7.
    • (1994) JAMA , vol.271 , pp. 672-677
    • McKenny, J.M.1    Proctor, J.D.2    Harris, S.3    Chinchili, V.M.4
  • 10
    • 0027407445 scopus 로고
    • Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium, and lovastatin) for treating hypercholesterolemic veterans
    • Schectman G, Hiatt J, Hartz A. Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium, and lovastatin) for treating hypercholesterolemic veterans. Am J Cardiol 1993;71:759-65.
    • (1993) Am J Cardiol , vol.71 , pp. 759-765
    • Schectman, G.1    Hiatt, J.2    Hartz, A.3
  • 11
    • 0021828236 scopus 로고
    • Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects. Clue to mechanism of action of niacin
    • Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects. Clue to mechanism of action of niacin. Metabolism 1985;34:642-50.
    • (1985) Metabolism , vol.34 , pp. 642-650
    • Knopp, R.H.1    Ginsberg, J.2    Albers, J.J.3
  • 12
    • 0028967825 scopus 로고
    • Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings?
    • Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332: 1125-31.
    • (1995) N Engl J Med , vol.332 , pp. 1125-1131
    • Andrade, S.E.1    Walker, A.M.2    Gottlieb, L.K.3
  • 13
    • 0029149881 scopus 로고    scopus 로고
    • The prevalence of side effects with regular and sustained-release nicotinic acid
    • Gibbons LW, Gonzalez V, Gordon N, Grundy S. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med 1996;99:378-85.
    • (1996) Am J Med , vol.99 , pp. 378-385
    • Gibbons, L.W.1    Gonzalez, V.2    Gordon, N.3    Grundy, S.4
  • 16
    • 0026509811 scopus 로고
    • Hepatic toxicity of unmodified and time-release preparations of niacin
    • Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992; 92:77-81.
    • (1992) Am J Med , vol.92 , pp. 77-81
    • Rader, J.I.1    Calvert, R.J.2    Hathcock, J.N.3
  • 17
    • 0027991884 scopus 로고    scopus 로고
    • Nicotinic acid as a lipoprotein-altering agent
    • Probstfield JL. Nicotinic acid as a lipoprotein-altering agent. Arch Intern Med 1996;154:1557-9.
    • (1996) Arch Intern Med , vol.154 , pp. 1557-1559
    • Probstfield, J.L.1
  • 18
    • 0025183769 scopus 로고
    • Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B
    • Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
    • (1990) N Engl J Med , vol.323 , pp. 1289-1298
    • Brown, G.1    Albers, J.J.2    Fisher, L.D.3
  • 19
    • 0028572530 scopus 로고
    • Cholesterol and coronary heart disease: Predicting risks by levels and ratios
    • Kinosian B, Click H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994;121:641-7.
    • (1994) Ann Intern Med , vol.121 , pp. 641-647
    • Kinosian, B.1    Click, H.2    Garland, G.3
  • 20
    • 0029122754 scopus 로고
    • Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis
    • Brown SL, Sobel BE, Fujii S. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. Circulation 1995;92:767-72.
    • (1995) Circulation , vol.92 , pp. 767-772
    • Brown, S.L.1    Sobel, B.E.2    Fujii, S.3
  • 21
    • 0027502421 scopus 로고
    • Susceptibility of small dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, type B
    • Chait A, Brazg RL, Tribble DL, Kraus RM. Susceptibility of small dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, type B. Am J Med 1993;94:350-6.
    • (1993) Am J Med , vol.94 , pp. 350-356
    • Chait, A.1    Brazg, R.L.2    Tribble, D.L.3    Kraus, R.M.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.